Catherex, Inc.
|
In April 2010, MediGene assigned its development program of oncolytic (cancer- killing) herpes simplex viruses (oHSV), to Catherex, Inc., a private US company located in Philadelphia, Pennsylvania. In return, MediGene received a 40% stake in Catherex, making MediGene the main shareholder of this newly founded company. MediGene is supporting the future development of the oHSV technology by appointing two persons to the Supervisory Board of Catherex. In addition, should the NV1020 project be further developed by Catherex, MediGene would be entitled to further stock options or a one-off payment. Furthermore, should Catherex grant licenses for defined rights within the oHSV program to certain third parties, MediGene would be eligible to receive further payments. Contact Catherex, Inc.
|